Inovio Q3 net loss $25.2M; INO-3107 BLA on track for mid-2025 submission

INOVIO PHARMACEUTICALS, INC.

2024-Q3 EPS reported -$3.35 revenue$100,762

Net loss of $25.2M ($0.89/share) vs $33.9M loss in Q3 2023; R&D expense $18.7M, G&A $8.6M.
Cash, equivalents and short-term investments $84.8M at Sept 30, 2024; cash runway into Q3 2025.
INO-3107 Phase 1/2 data: 81% of 32 patients had fewer surgeries; 28% had zero surgeries post-treatment.
All non-device BLA modules for INO-3107 on track for completion by year-end 2024; BLA submission targeted mid-2025.
Advancing Phase 3 plan for INO-3112 in HPV+ throat cancer; Phase 2 Ebola vaccine booster trial in FDA discussions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.